加拿大EVAR支架移植物取出术的多中心结局经验
这项加拿大13中心回顾性研究分析了2003至2018年111例EVAR支架移植物取出术,平均年龄74岁、动脉瘤平均7.5cm,最常见指征为内漏(66例)。总体30天死亡率为11%,破裂(33.3%)和感染(15%)患者死亡率显著高于择期内漏取出者(4.5%,P=.003)。
要点
- EVAR取出术30天死亡率为11%,45%患者发生至少一种主要围手术期并发症。
- 破裂和感染患者取出死亡率显著高于择期内漏取出(33.3%、15% vs 4.5%,P=.003)。
- 有取出指征者应在症状或破裂发生前接受手术,低容量中心死亡趋势更高但未达统计学意义。
核心结论
- 加拿大EVAR支架移植物取出术数量在增加,择期内漏取出死亡率低于感染或破裂取出。
- 有取出指征的患者应在症状或破裂发生前接受手术。
- 低容量中心(少于8例)患者死亡趋势更高但未达统计学显著性(19% vs 9%,P=.23)。
研究设计与样本
- 加拿大血管外科学组开展的回顾性多中心研究,纳入2003至2018年参与中心的全部EVAR支架移植物取出病例。
- 数据通过标准化安全在线平台RedCap收集,采用单变量统计分析比较不同取出指征的技术与结局。
- 共分析来自13个参与中心的111例EVAR取出数据。
主要发现
- 取出时平均年龄74岁,平均动脉瘤大小7.5cm,28%在EVAR时至少有一项使用说明违规。
- EVAR至取出平均时间42.5个月;最常见指征为内漏(n=66;Ia型46、Ib型2、II型9、III型2、V型7),其次感染20例、破裂18例、移植物血栓7例。
- 总体30天死亡率11%,45%患者经历至少一种主要围手术期并发症。
- 破裂患者死亡率33.3%、感染患者15%,显著高于择期内漏取出患者的4.5%(P=.003)。
- 41%患者在取出前至少尝试过一次腔内挽救,内漏取出者中比例最高(51%),破裂患者中仅22%尝试过腔内挽救。
关键数值与推荐
- 总体30天死亡率为11%,主要围手术期并发症发生率为45%。
- 破裂、感染与择期内漏取出患者死亡率分别为33.3%、15%与4.5%(P=.003)。
- 过去15年平均中心容量为8例(范围2-19例);少于8例与8例及以上中心死亡率分别为19%与9%(P=.23)。
- 破裂患者中仅22%在取出前尝试过腔内挽救,内漏取出患者中为51%。
临床怎么用
- 对存在EVAR取出指征的患者,应在症状出现或破裂前择期手术以降低死亡率。
- 内漏是取出的最常见指征,择期内漏取出死亡率低于感染或破裂取出。
- 低容量中心开展EVAR取出术时需关注死亡风险趋势,但本研究未达统计学显著性。
局限性
- 回顾性多中心研究设计,可能存在选择偏倚与数据收集不完整。
- 中心容量分析中少于8例与8例及以上中心的死亡率差异未达统计学显著性(P=.23)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most studies describing the outcomes after endovascular abdominal aortic aneurysm repair (EVAR) explantation have been from single, high-volume, centers. We performed a multicenter cross-Canadian study of outcomes after EVAR stent graft explantation. Our objectives were to describe the outcomes after late open conversion and EVAR graft explantation at various Canadian centers and the techniques and outcomes stratified by the indication for explant. METHODS: The Canadian Vascular Surgery Research Group performed a retrospective multicenter study of all cases of EVAR graft explantation at participating centers from 2003 to 2018. Data were collected using a standardized, secure, online platform (RedCap [Research Electronic Data Capture]). Univariate statistical analysis was used to compare the techniques and outcomes stratified the indication for graft explantation. RESULTS: Patient data from 111 EVAR explants collected from 13 participating centers were analyzed. The mean age at explantation was 74 years, the average aneurysm size was 7.5 cm, and 28% had had at least one instructions for use violation at EVAR. The average time between EVAR and explantation was 42.5 months. The most common indication for explantation was endoleak (n = 66; type Ia, 46; type Ib, 2; type II, 9; type III, 2; type V, 7), followed by infection in 20 patients; rupture in 18 patients (due to type Ia endoleak in 10 patients, type Ib in 1, type II in 1, type III in 2, and type V in 1), and graft thrombosis in 7 patients. The overall 30-day mortality was 11%, and 45% of the patients had experienced at least one major perioperative complication. Mortality was significantly greater for patients with rupture (33.3%) and those with infection (15%) compared with patients undergoing elective explantation for endoleak (4.5%; P = .003). The average center volume during the previous 15 years was 8 cases with a wide range (2-19 cases). A trend was seen toward greater mortality for patients treated at centers with fewer than eight cases compared with those with eight or more cases (19% vs 9%). However, the difference did not reach statistical significance (P = .23). Overall, 41% of patients had undergone at least one attempt at endovascular salvage before explantation, with the highest proportion among patients who had undergone EVAR explantation for endoleak (51%). Only 22% of patients with rupture had undergone an attempt at endovascular salvage before explantation. CONCLUSIONS: The performance of EVAR graft explantation has increasing in Canada. Patients who had undergone elective explantation for endoleak had lower mortality than those treated for either infection or rupture. Thus, patients with an indication for explanation should be offered surgery before symptoms or rupture has occurred. A trend was seen toward greater mortality for patients treated at centers with lower volumes.
引用
- Dubois L, Harlock J, Gill HL, et al. A Canadian multicenter experience describing outcomes after endovascular abdominal aortic aneurysm repair stent graft explantation. J Vasc Surg. 2021. PMID: 33600929. doi:10.1016/j.jvs.2021.01.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。